Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | TYMS | P04818 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16243070 | 0.91 | AADAT (0.41) | AADATGAASMN1; SMN2TYMSDRD3 | |
| SCHEMBL16242764 | 0.90 | AADAT (0.45) | AADATGAAOPRM1OPRL1SMN1; SMN2 | |
| SCHEMBL16242751 | 0.90 | AADAT (0.42) | AADATGAASMN1; SMN2DRD3 | |
| SCHEMBL12503423 | 0.85 | AADAT (0.39) | AADATGAASMN1; SMN2TYMS | |
| SCHEMBL16242992 | 0.85 | SMN1; SMN2 (0.46) | SMN1; SMN2DRD3HRH3 | |
| SCHEMBL367029 | 0.85 | SIGMAR1 (0.45) | AADATGAASMN1; SMN2MAPT | |
| SCHEMBL367366 | 0.85 | AADAT (0.47) | AADATGAASMN1; SMN2 | |
| SCHEMBL366569 | 0.84 | AADAT (0.43) | AADATGAASMN1; SMN2CYP3A4CYP2C19 | |
| SCHEMBL15129805 | 0.84 | HRH3 (0.45) | AADATGAADRD3HRH3 | |
| SCHEMBL15129782 | 0.84 | AADAT (0.45) | AADATGAASMN1; SMN2CYP2C19HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765091-B2 | Tetrahydropyrazolo [3,4-b] azepine derivatives and their use as allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMA S.A. (CH) | 2017-09-19 | — | — | US | disclosed |
| EP-2592932-B1 | NOVEL TETRAHYDROPYRAZOLO[3,4-B]AZEPINE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2016-01-20 | — | — | EP | disclosed |
| US-20130267499-A1 | NOVEL TETRAHYDROPYRAZOLO [3,4-b] AZEPINE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2013-10-10 | — | — | US | disclosed |
| EP-2592932-A2 | NOVEL TETRAHYDROPYRAZOLO[3,4-B]AZEPINE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharma SA (CH) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012009001-A2 | NOVEL TETRAHYDROPYRAZOLO[3,4-B]AZEPINE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA S.A. (CH) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267499-A1 | NOVEL TETRAHYDROPYRAZOLO [3,4-b] AZEPINE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM4, GRM1, GRIK4 | AADAT 494/4885GAA 3198/4885OPRM1 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.